Olesya A. Kharenko

32 Royal Vista Drive NW, Suite 105
Calgary, AB T3R0H9, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Tumor-Immune Cell Crosstalk Drives Immune Cell Reprogramming Towards a Pro-Tumor Proliferative State Involving STAT3 Activation.

Tumor-Immune Cell Crosstalk Drives Immune Cell Reprogramming Towards a Pro-Tumor Proliferative State Involving STAT3 Activation.

Journal: Cancers

Published: December 05, 2025

Editorial: Liquid-biopsy-guided biomarker and drug discovery.

Editorial: Liquid-biopsy-guided biomarker and drug discovery.

Journal: Frontiers in pharmacology

Published: June 26, 2024

Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators.

Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: April 01, 2022

Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer.

Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer.

Journal: Cancer gene therapy

Published: April 30, 2021

Synthesis of NVS-BPTF-1 and evaluation of its biological activity.

Synthesis of NVS-BPTF-1 and evaluation of its biological activity.

Journal: Bioorganic & medicinal chemistry letters

Published: April 29, 2021

Design and Characterization of Novel Covalent Bromodomain and Extra-Terminal Domain (BET) Inhibitors Targeting a Methionine.

Design and Characterization of Novel Covalent Bromodomain and Extra-Terminal Domain (BET) Inhibitors Targeting a Methionine.

Journal: Journal of medicinal chemistry

Published: August 31, 2018

Novel approaches to targeting BRD4.

Novel approaches to targeting BRD4.

Journal: Drug discovery today. Technologies

Published: December 21, 2016

RVX-297- a novel BD2 selective inhibitor of BET bromodomains.

RVX-297- a novel BD2 selective inhibitor of BET bromodomains.

Journal: Biochemical and biophysical research communications

Published: May 12, 2016

Discovery of a new chemical series of BRD4(1) inhibitors using protein-ligand docking and structure-guided design.

Discovery of a new chemical series of BRD4(1) inhibitors using protein-ligand docking and structure-guided design.

Journal: Bioorganic & medicinal chemistry letters

Published: March 12, 2015

Identification and characterization of interactions between abscisic acid and human heat shock protein 70 family members.

Identification and characterization of interactions between abscisic acid and human heat shock protein 70 family members.

Journal: Journal of biochemistry

Published: August 27, 2013

RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist.

RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist.

Journal: PloS one

Published: July 06, 2013

Abscisic acid binds to recombinant Arabidopsis thaliana G-protein coupled receptor-type G-protein 1 in Sacaromycese cerevisiae and in vitro.

Abscisic acid binds to recombinant Arabidopsis thaliana G-protein coupled receptor-type G-protein 1 in Sacaromycese cerevisiae and in vitro.

Journal: Plant physiology and biochemistry : PPB

Published: February 27, 2013

Showing 1-12 of 13

Last Updated: 09/26/2026